AJG: There was a significant increase in the incidence of substrate cell carcinoma in patients with inflammatory bowel disease treated with immunosuppressive drugs.

Background and objective: It is not uncommon in clinical lysis in patients with inflammatory bowel disease (IBD) to have repeated lysomatic cell carcinoma (BCC), especially with a significant increase in the probability of continuous use of immunosuppressive drugs.
whether such correlations are real or not has not been explored, and this study is intended to be an attempt to do so.
method: The researchers conducted retrospective cohort studies of 54,919 patients with IBD.
researchers defined patient exposure based on the use of IBD drugs: (i) only amino salphate (5-ASA), (ii) thiopental (TP), (iii) past TP use (3) (iv) anti-TNF after previous use, (v) anti-TNF only, and (vi) anti-TNF and TP activity.
the main observation outcome is the recurrence of BCC.
use the adjusted and unadjusted risk ratio of the 95% confidence interval to estimate the risk of duplicate BCC.
Results: This study shows that a total of 518 patients developed BCC.
the number of times BCC is repeated per 100 people per 100 people is 12.8 (5-ASA only), 34.5 (TP use only), 19.3 (past TP used and not used anti-TNF), 25.4 (previously used anti-TNF), 17.8 (anti-TNF only) and 22.4 (effective use of anti-TNF and TP).
active use of TP alone increases the risk of recurring BCC compared to using 5-ASA alone (adjusted risk ratio 1.65, 95% confidence interval 1.24-2.19; P s 0.0005).
, however, there is no longer an increased risk in other exposure categories.
conclusion: The probability of BCC events increased significantly in IBD patients treated with thiopental drugs, while other drugs do not lead to an increased risk of BCC occurrence.
.